In­te­grat­ing In­no­va­tion into Health­care: No­var­tis

FICCI Business Digest - - Features -

Mi­lan Paleja, Coun­try Pres­i­dent, No­var­tis In­dia speaks to Business Di­gest about No­var­tis's fu­ture plans:

No­var­tis is known for us­ing science-based in­no­va­tion to ad­dress the most chal­leng­ing health­care is­sues. Please share some of the in­no­va­tions you have un­der­taken and their im­pact.

No­var­tis strat­egy is to use sci­ence­based in­no­va­tion to de­liver bet­ter pa­tient out­comes in grow­ing ar­eas of health­care. Ex­am­ples we would like to share are treat­ment of heart fail­ure, breast can­cer and pso­ri­a­sis with our in­no­va­tive mol­e­cules, Vy­mada, Kryx­ana and Scapho, all of which were in­tro­duced in In­dia soon after their global launch. We have suc­ceeded in get­ting ac­cess to these in­no­va­tive mol­e­cules to an in­creas­ing num­ber of pa­tients. Our aim is to in­crease ac­cess to our new medicines by find­ing new ways to de­liver them.

Pri­vate sec­tor has been lead­ing the health­care in­dus­try for decades, how­ever, the gov­ern­ment with its new ini­tia­tives such as 'Ayush­man Bharat' is mak­ing head­way in the sec­tor. In such a sce­nario, how do you per­ceive the role of pri­vate sec­tor in the fu­ture?

At No­var­tis we fo­cus on pa­tients in both the pri­vate and pub­lic sec­tors. We are very pleased with the gov­ern­ment for tak­ing health as a pri­or­ity and putting in place the Na­tional Health Pro­tec­tion Mis­sion (NHPM). We are keen to part­ner with var­i­ous stake­hold­ers to ad­dress the needs of pa­tients through NHPM. While NHPM is cur­rently re­stricted to hos­pi­tal­i­sa­tion, we hope that it will widen its scope to cover chronic dis­eases in the com­ing years.

In­dia faces im­mense is­sues while pro­vid­ing health­care ser­vices to its bur­geon­ing pop­u­la­tion. How does No­var­tis pro­pose to ful­fill its com­mit­ment to pa­tients and care­givers?

At No­var­tis we have a strong com­mit­ment to pa­tients and care­givers through our tai­lored ac­cess so­lu­tions in­clud­ing man­aged ac­cess pro­grammes of­fer­ing pa­tients ac­cess to our in­no­va­tive medicines that are not avail­able in In­dia. Our of­fer­ings in­clude In­dia pric­ing for our in­no­va­tive drugs, full do­na­tion pro­grammes, co-pay pro­grammes and pa­tient sup­port pro­grammes in­clud­ing coun­selling. We also ed­u­cate care­givers on man­age­ment of chronic dis­eases lead­ing to bet­ter care of the pa­tient. We have a wellestab­lished so­cial business pro­gramme called Ar­o­gya Pari­var, which has been in ex­is­tence for over 10 years, serv­ing ru­ral In­dia across 11 states. In 2017 alone, Ar­o­gya Pari­var touched the lives of 7.4 mil­lion peo­ple through close to 150,000 health ed­u­ca­tion meet­ings and 9,000 health camps. In ad­di­tion, over the last two years we have con­ducted more than 12,000 sci­en­tific en­gage­ments for and with the med­i­cal com­mu­nity to fur­ther aug­ment their sci­en­tific knowl­edge, en­abling them to ex­tend the ben­e­fits of our prod­uct port­fo­lio.

No­var­tis is also known for its Cor­po­rate So­cial Re­spon­si­bil­ity ini­tia­tives. Please high­light some of the or­gan­i­sa­tion's work in this area.

No­var­tis is com­mit­ted to bring­ing its medicines to more and more peo­ple. For all our new medicines, No­var­tis has com­mit­ted to in­te­grate strate­gies in how we re­search, de­velop and de­liver these medicines world­wide. Some ex­am­ples of our CSR work are:

Lep­rosy

Ÿ Since 2000, No­var­tis has been do­nat­ing the world's sup­ply of lep­rosy drugs via WHO. In­dia, with around 60 per cent of the world's case load, is the largest re­cip­i­ent. Ÿ To­gether with No­var­tis Foun­da­tion we have part­nered with the Nether­lands Lep­rosy Re­lief for a lep­rosy pos­t­ex­po­sure pro­phy­laxis project to stop the trans­mis­sion of lep­rosy. Ÿ No­var­tis In­dia to­gether with No­var­tis Foun­da­tion is work­ing on a dig­i­tal tool to en­able in­de­pen­dent early screen­ing for lep­rosy us­ing ar­ti­fi­cial in­tel­li­gence (AI) and deep learn­ing.

Can­cer

Ÿ Since 2002, No­var­tis In­dia has pro­vided pa­tients suf­fer­ing from chronic myeloid leukemia and gas­tro-in­testi­nal tu­mours with in­no­va­tive drug Glivec com­pletely free of charge. Cur­rently, more than 16,000 pa­tients have re­ceived the drug ab­so­lutely free.

With the ad­vent of new tech­nolo­gies, as the Coun­try Pres­i­dent what are your ex­pan­sion plans for No­var­tis in the next decade?

We, at No­var­tis, be­lieve that data and dig­i­tal­i­sa­tion are go­ing to shape the fu­ture of how health­care will ben­e­fit lives of pa­tients. There­fore, as an or­gan­i­sa­tion we are in­vested in bring­ing about an at­ti­tu­di­nal shift by driv­ing dig­i­tal adop­tion both in­ter­nally and ex­ter­nally. Since 2013, we have been con­stantly in­vest­ing in build­ing a dig­i­tal ecosys­tem. We are up­skilling our as­so­ci­ates to lever­age the wide­spread dig­i­tal trans­for­ma­tion tak­ing place across in­dus­try and mar­kets. We are also ex­plor­ing the use of smart­phones to im­prove dis­ease man­age­ment and to col­late in­for­ma­tion to de­velop real world ev­i­dence (RWE).

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.